Antihyperglycaemic therapies and cancer risk

Conclusion: Although the molecular mechanisms are not fully understood, a potential risk of mitogenicity and tumour growth promotion cannot be excluded in case of several antidiabetic drug classes. However, more large-scale, randomized, well-designed clinical studies with especially long follow-up time periods are needed to get reliable answers to these safety issues.
Source: Diabetes and Vascular Disease Research - Category: Endocrinology Authors: Tags: Invited Reviews Source Type: research